Skip to main content
SpringerLink
Log in

Development of Bile Acids as Anti-Apoptotic and Neuroprotective Agents in Treatment of Ocular Disease

  • Chapter
  • First Online:
Drug Product Development for the Back of the Eye

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 2))

Abstract

The hydrophilic bile acids ursodeoxycholic acid and tauroursodeoxycholic acid are approved by regulatory bodies of many countries for treatment of gallstones and cirrhosis. Delivery is by oral administration and side effects are minimal. This chapter reviews evidence demonstrating that systemic treatment with the two compounds is protective in models of neuronal and retinal degeneration and injury. Variability in the regulation of circulating bile acids suggests a need to explore local delivery as a treatment modality. Our initial experiments testing in vivo intraocular injections and in vitro transscleral permeability indicate that this is feasible and efficacious.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM (2009) Bile acids: regulation of apoptosis by ursodeoxycholic ccid. J Lipid Res 50:1721–1734

    Article  PubMed  CAS  Google Scholar 

  • Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF (2008) Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Investig 118:695–709

    PubMed  CAS  Google Scholar 

  • Arora SK, Faulkner A, Kim M, Ciavatta V, Pardue M (2009) Tudca preserves cones in fast degenerating Rd1 mice. Invest Ophthalmol Vis Sci 50:E-Abstract 978

    Google Scholar 

  • Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S (1989) Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 30:1953–1962

    PubMed  CAS  Google Scholar 

  • Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O’Brien CB, Senior JR (1993) Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 88:691–700

    PubMed  CAS  Google Scholar 

  • Boatright JH, Boyd AP, Sidney SS, Minear SC, Stewart RE, Chaudhury R, Ciavatta VT (2006a) Effect of tauroursodeoxycholic acid on light-induced retinal degeneration. ARVO Meet Abstr 47:4835

    Google Scholar 

  • Boatright JH, Moring AG, McElroy C, Phillips MJ, Do VT, Chang B, Hawes NL, Boyd AP, Sidney SS, Stewart RE, Minear SC, Chaudhury R, Ciavatta VT, Rodrigues CM, Steer CJ, Nickerson JM, Pardue MT (2006b) Tool from ancient pharmacopoeia prevents vision loss. Mol Vis 12:1706–1714

    PubMed  CAS  Google Scholar 

  • Boatright JH, Nickerson JM, Moring AG, Pardue MT (2009a) Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor 2:149–159

    Article  PubMed  Google Scholar 

  • Boatright JH, Sidney SS, Kim ES, Nickerson JM, Edelhauser HF (2009b) Transscleral permeability of tauroursodeoxycholic acid. ARVO Meet Abstr 50:5958

    Google Scholar 

  • Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB (1990) Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature 347:677–680

    Article  PubMed  CAS  Google Scholar 

  • Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM (2004) The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 311:845–852

    Article  PubMed  CAS  Google Scholar 

  • Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR (2002) Retinal degeneration mutants in the mouse. Vis Res 42:517–525

    Article  PubMed  CAS  Google Scholar 

  • Chang B, Hawes NL, Pardue MT, German AM, Hurd RE, Davisson MT, Nusinowitz S, Rengarajan K, Boyd AP, Sidney SS, Phillips MJ, Stewart RE, Chaudhury R, Nickerson JM, Heckenlively JR, Boatright JH (2007) Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. Vis Res 47:624–633

    Article  PubMed  CAS  Google Scholar 

  • Chen L, Dentchev T, Wong R, Hahn P, Wen R, Bennett J, Dunaief JL (2003) Increased expression of ceruloplasmin in the retina following photic injury. Mol Vis 9:151–158

    PubMed  CAS  Google Scholar 

  • Colak A, Kelten B, Sagmanligil A, Akdemir O, Karaoglan A, Sahan E, Celik O, Barut S (2008) Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. J Clin Neurosci 15:665–671

    Article  PubMed  CAS  Google Scholar 

  • Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M (1996) Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci 41:809–815

    Article  PubMed  CAS  Google Scholar 

  • Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548

    Article  PubMed  CAS  Google Scholar 

  • Do VT, Nickerson JM, Boatright JH (2003) Prevention of apoptosis in an RPE carcinoma cell line by bile acids. ARVO Meet Abstr 44:4550

    Google Scholar 

  • Duan WM, Rodrigues CM, Zhao LR, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson’s disease. Cell Transplant 11:195–205

    PubMed  Google Scholar 

  • Fedorowski T, Salen G, Calallilo A, Tint GS, Mosbach EH, Hall JC (1977) Metabolism of ursodeoxycholic acid in man. Gastroenterology 73:1131–1137

    PubMed  CAS  Google Scholar 

  • Fernandez-Sanchez L, Pinilla I, Campello L, Idiope M, Martin-Nieto J, Cuenca N (2008) Tauroursodeoxycholic acid (TUDCA) slows retinal degeneration in transgenic P23H rats. Invest Ophthalmol Vis Sci 49:E-Abstract 2195

    Google Scholar 

  • Fernandez-Sanchez L, Lax P, Esquiva G, Pinilla I, Martín-Niet J, Cuenca N (2009) Loss of synaptic contacts in the retina is prevented by tauroursodeoxycholic acid (TUDCA) in transgenic P23H rats. Invest Ophthalmol Vis Sci 50:E-Abstract 980

    Google Scholar 

  • Foster SL, Ziesel AC, Kendall C, Boatright JH (2009) Of mice and men: the search for polymorphisms in the SLCO1b2 gene. In: SURE program, Emory University, Atlanta, GA, p 20

    Google Scholar 

  • Gargini C, Terzibasi E, Mazzoni F, Strettoi E (2007) Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J Comp Neurol 500:222–238

    Article  PubMed  Google Scholar 

  • German Moring AJ, Nickerson JM, Boatright JH (2003) Protective effects of tauroursodeoxycholic acid against oxidative damage in human retinoblastoma cells. ARVO Meet Abstr 44:4551

    Google Scholar 

  • Hofmann AF (1994) Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 204:1–15

    Article  CAS  Google Scholar 

  • Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647–2658

    Article  PubMed  CAS  Google Scholar 

  • Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O’Connell NC, Podda M (1999) Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 29:320–327

    Article  PubMed  CAS  Google Scholar 

  • Joo SS, Won TJ, Lee DI (2004) Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch Pharm Res 27:954–960

    Article  PubMed  CAS  Google Scholar 

  • Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol 171:351–360

    Article  PubMed  CAS  Google Scholar 

  • Kendall C, Premji SM, Stewart RE, Stewart RA, Boatright JH (2008) Ocular delivery of TUDCA provides neuroprotection in a mouse model of retinal degeneration. ARVO Meet Abstr 49:4932

    Google Scholar 

  • Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K (1997) Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25:1077–1084

    Article  PubMed  CAS  Google Scholar 

  • Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506

    Article  PubMed  CAS  Google Scholar 

  • Mulhern ML, Madson CJ, Thoreson W, Shinohara T (2008) Chemical chaperones and TUDCA partially suppress degeneration of retinal photoreceptor cells in transgenic mutant rhodopsin S334ter-3 rats. Invest Ophthalmol Vis Sci 49:E-Abstract 2038

    Google Scholar 

  • Nakagawa M, Colombo C, Setchell KD (1990) Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 12:322–334

    Article  PubMed  CAS  Google Scholar 

  • Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T et al (1990) A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 25:774–780

    PubMed  CAS  Google Scholar 

  • Oveson BC, Iwase T, Hackett SF, Lee SY, Usui S, Sedlak TW, Snyder SH, Campochiaro PA, Sung JU (2011) Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. J Neurochem 116:144–153

    Article  PubMed  CAS  Google Scholar 

  • Park IH, Kim MK, Kim SU (2008) Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation. Biochem Biophys Res Commun 377:1025–1030

    Article  PubMed  CAS  Google Scholar 

  • Parquet M, Metman EH, Raizman A, Rambaud JC, Berthaux N, Infante R (1985) Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man. Eur J Clin Investig 15:171–178

    Article  CAS  Google Scholar 

  • Parry GJ, Rodrigues CM, Aranha MM, Hilbert SJ, Davey C, Kelkar P, Low WC, Steer CJ (2010) Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 33:17–21

    Article  PubMed  CAS  Google Scholar 

  • Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36:525–531

    Article  PubMed  CAS  Google Scholar 

  • Phillips MJ, Walker TA, Choi HY, Faulkner AE, Kim MK, Sidney SS, Boyd AP, Nickerson JM, Boatright JH, Pardue MT (2008) Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30. Investig Ophthalmol Vis Sci 49:2148–2155

    Article  Google Scholar 

  • Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM (2006) Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cells. J Neurochem 98:1610–1618

    Article  PubMed  CAS  Google Scholar 

  • Ramalho RM, Viana RJ, Castro RE, Steer CJ, Low WC, Rodrigues CM (2008a) Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med 14:309–317

    Article  PubMed  CAS  Google Scholar 

  • Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM (2008b) Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer’s disease. Trends Mol Med 14:54–62

    Article  PubMed  CAS  Google Scholar 

  • Reme CE, Grimm C, Hafezi F, Marti A, Wenzel A (1998) Apoptotic cell death in retinal degenerations. Prog Retin Eye Res 17:443–464

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ (1998) Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4:165–178

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ (1999) Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 6:842–854

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, Steer CJ (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75:2368–2379

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ (2001) Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 281:468–474

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Spellman SR, Sola S, Grande AW, Linehan-Stieers C, Low WC, Steer CJ (2002) Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab 22:463–471

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ (2003a) Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci USA 100:6087–6092

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues CM, Sola S, Sharpe JC, Moura JJ, Steer CJ (2003b) Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry 42:3070–3080

    Article  PubMed  CAS  Google Scholar 

  • Rubin RA, Kowalski TE, Khandelwal M, Malet PF (1994) Ursodiol for hepatobiliary disorders. Ann Intern Med 121:207–218

    PubMed  CAS  Google Scholar 

  • Setchell KD, Rodrigues CM, Podda M, Crosignani A (1996) Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 38:439–446

    Article  PubMed  CAS  Google Scholar 

  • Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM (2003) Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med 9:226–234

    Article  PubMed  CAS  Google Scholar 

  • Sola S, Aranha MM, Steer CJ, Rodrigues CM (2007) Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr Issues Mol Biol 9:123–138

    PubMed  CAS  Google Scholar 

  • Steinberg RH, Flannery JG, Naash M, Oh P, Matthes MT, Yasumura D, Lau-Villacorta C, Chen J, LaVail MM (1996) Transgenic rat models of inherited retinal degeneration caused by mutant opsin genes. Investig Ophthalmol Vis Sci 37:S698

    Google Scholar 

  • Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, Bircher J, Folsch U, Klaus J, Endele R et al (1990) Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 12:492–497

    Article  PubMed  CAS  Google Scholar 

  • Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S (1982) Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med 97:351–356

    PubMed  CAS  Google Scholar 

  • van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH (2010) Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Investig 120:2942–2952

    Article  PubMed  Google Scholar 

  • Viana RJ, Nunes AF, Castro RE, Ramalho RM, Meyerson J, Fossati S, Ghiso J, Rostagno A, Rodrigues CM (2009) Tauroursodeoxycholic acid prevents E22Q Alzheimer’s Abeta toxicity in human cerebral endothelial cells. Cell Mol Life Sci 66:1094–1104

    Article  PubMed  CAS  Google Scholar 

  • Walker S, Rudolph G, Raedsch R, Stiehl A (1992) Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 102:810–815

    PubMed  CAS  Google Scholar 

  • Weitzel C, Stark D, Kullmann F, Scholmerich J, Holstege A, Falk W (2005) Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 17:169–177

    Article  PubMed  CAS  Google Scholar 

  • Woo SJ, Kim JH, Yu HG (2010) Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model. J Ocul Pharmacol Ther 26:223–229

    Article  PubMed  CAS  Google Scholar 

  • Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M (2009) Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet Genomics 19:447–457

    Article  PubMed  CAS  Google Scholar 

  • Yang ES, Kendall C, Premji SM, Boatright JH (2008) Tauroursodeoxycholic acid (TUDCA) prevents loss of visual function in rats. Invest Ophthalmol Vis Sci 49:E-Abstract 4933

    Google Scholar 

Download references

Acknowledgments

Original work presented here was supported in part by The Abraham J. and Phyllis Katz Foundation, the Foundation Fighting Blindness (FFB), Research to Prevent Blindness (RPB), and NIH NEI grants R01EY014026, R01EY016470, R24EY017045, P30EY006360, and T32EY007092.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA

    Stephanie L. Foster, Cristina Kendall MS, Allia K. Lindsay BS, Alison C. Ziesel BS, Rachael S. Allen MS, Sheree S. Mosley BS & Esther S. Kim BS

  2. Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada

    Alison C. Ziesel BS

  3. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Ross J. Molinaro PhD

  4. Emory University Eye Center, Emory University, Atlanta, GA, USA

    Henry F. Edelhauser PhD

  5. Department of Ophthalmology and Rehabilitation Research and Development Center of Excellence, Atlanta VA Medical Center, Emory University School of Medicine, Atlanta, GA, USA

    Machelle T. Pardue PhD

  6. Department of Ophthalmology, Emory University, Atlanta, GA, USA

    John M. Nickerson PhD

  7. Department of Ophthalmology, Emory University School of Medicine, B5511 Emory Eye Center, 1365-B Clifton Road, Atlanta, GA, 30322, USA

    Jeffrey H. Boatright PhD

Authors
  1. Stephanie L. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Kendall MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allia K. Lindsay BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alison C. Ziesel BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachael S. Allen MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheree S. Mosley BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Esther S. Kim BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ross J. Molinaro PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Henry F. Edelhauser PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Machelle T. Pardue PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. John M. Nickerson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jeffrey H. Boatright PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey H. Boatright PhD .

Editor information

Editors and Affiliations

  1. School of Pharmacy, University of Colorado Denver, East 17th Avenue 12631, Aurora, 80045, Colorado, USA

    Uday B. Kompella

  2. School of Medicine, Emory University, Clifton Road NE., 1365, Atlanta, 30322, Georgia, USA

    Henry F. Edelhauser

Rights and permissions

Reprints and permissions

Copyright information

© 2011 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Foster, S.L. et al. (2011). Development of Bile Acids as Anti-Apoptotic and Neuroprotective Agents in Treatment of Ocular Disease. In: Kompella, U., Edelhauser, H. (eds) Drug Product Development for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9920-7_22

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation